JP2017529365A5 - - Google Patents

Download PDF

Info

Publication number
JP2017529365A5
JP2017529365A5 JP2017515823A JP2017515823A JP2017529365A5 JP 2017529365 A5 JP2017529365 A5 JP 2017529365A5 JP 2017515823 A JP2017515823 A JP 2017515823A JP 2017515823 A JP2017515823 A JP 2017515823A JP 2017529365 A5 JP2017529365 A5 JP 2017529365A5
Authority
JP
Japan
Prior art keywords
alkyl
het
halo
independently
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017515823A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017529365A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/071349 external-priority patent/WO2016042089A1/en
Publication of JP2017529365A publication Critical patent/JP2017529365A/ja
Publication of JP2017529365A5 publication Critical patent/JP2017529365A5/ja
Pending legal-status Critical Current

Links

JP2017515823A 2014-09-17 2015-09-17 大環状lrrk2キナーゼ阻害剤 Pending JP2017529365A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14290279.0 2014-09-17
EP14290279 2014-09-17
PCT/EP2015/071349 WO2016042089A1 (en) 2014-09-17 2015-09-17 Macrocyclic lrrk2 kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2017529365A JP2017529365A (ja) 2017-10-05
JP2017529365A5 true JP2017529365A5 (enExample) 2018-09-13

Family

ID=51752058

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017515823A Pending JP2017529365A (ja) 2014-09-17 2015-09-17 大環状lrrk2キナーゼ阻害剤

Country Status (20)

Country Link
US (1) US10377772B2 (enExample)
EP (1) EP3194405B1 (enExample)
JP (1) JP2017529365A (enExample)
KR (1) KR20170048599A (enExample)
CN (1) CN107108641A (enExample)
AU (1) AU2015316801B2 (enExample)
BR (1) BR112017005299A2 (enExample)
CA (1) CA2960777A1 (enExample)
DK (1) DK3194405T3 (enExample)
EA (1) EA032838B1 (enExample)
ES (1) ES2717510T3 (enExample)
HU (1) HUE043972T2 (enExample)
IL (1) IL251054B (enExample)
MX (1) MX2017003470A (enExample)
PL (1) PL3194405T4 (enExample)
SG (1) SG11201701936WA (enExample)
TR (1) TR201904514T4 (enExample)
TW (1) TW201625639A (enExample)
WO (1) WO2016042089A1 (enExample)
ZA (1) ZA201701841B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111221514B (zh) * 2020-01-13 2023-03-03 陕西心像信息科技有限公司 基于OsgEarth的三维可视化组件实现方法及系统
AR124556A1 (es) * 2020-01-31 2023-04-12 Oncodesign Sa Inhibidores macrocíclicos de rip2-cinasa
UA129504C2 (uk) 2020-05-06 2025-05-14 Ле Лаборатуар Сервьє Нові макроциклічні інгібітори lrrk2-кінази
TW202304935A (zh) 2021-03-18 2023-02-01 法商施維雅藥廠 新穎的巨環lrrk2激酶抑制劑
WO2023064768A1 (en) * 2021-10-11 2023-04-20 Baylor College Of Medicine G-protein-coupled receptor regulators and methods of use thereof
WO2023073013A1 (en) * 2021-10-27 2023-05-04 H. Lundbeck A/S Lrrk2 inhibitors
CN117425660A (zh) * 2022-05-18 2024-01-19 上海翊石医药科技有限公司 一种芳杂环类化合物及其中间体、药物组合物和用途
TW202412777A (zh) 2022-09-15 2024-04-01 丹麥商H 朗德貝克公司 富白胺酸重複激酶2(lrrk2)抑制劑
WO2024218285A1 (en) * 2023-04-20 2024-10-24 H. Lundbeck A/S Leucine-rich repeat kinase 2 (lrrk2) inhibitors
AR132488A1 (es) * 2023-04-20 2025-07-02 H Lundbeck As Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2)
AR132487A1 (es) * 2023-04-20 2025-07-02 H Lundbeck As Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2)
WO2024218296A1 (en) * 2023-04-20 2024-10-24 H. Lundbeck A/S Combination treatments comprising administration of leucine-rich repeat kinase 2 (lrrk2) inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
SK283569B6 (sk) 1993-10-01 2003-09-11 Astra Aktiebolag Spôsob spracovania jemne deleného práškového liečiva, zariadenie na vykonávanie tohto spôsobu a aglomeráty vyrobené týmto spôsobom
EP0729758A3 (en) 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
EP0915880B1 (en) 1996-07-24 2007-10-10 Bristol-Myers Squibb Pharma Company Azolo triazines and pyrimidines
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
PT1354884E (pt) 2000-12-28 2007-12-24 Ono Pharmaceutical Co Composto de ciclopenta (d) pirazolo [1,5-a] piramida como antagonista de receptor de crf
US7067507B2 (en) * 2001-06-12 2006-06-27 Pharmacia & Upjohn Company Macrocycles useful in the treatment of Alzheimer's disease
WO2006045392A2 (en) 2004-10-21 2006-05-04 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Kaspp (lrrke) gene, its production and use for the detection and treatment of neurodegenerative disorders
NO323175B1 (no) 2004-12-23 2007-01-15 Jan O Aasly Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme
FI123725B (fi) 2005-08-01 2013-10-15 Reijo Viljanen Menetelmä sahalaitteen terän jännittämiseksi ja ohjaamiseksi sekä ohjaus- ja jännityslaitteet
PH12012501003B1 (en) 2005-11-16 2018-04-06 Cti Biopharma Corp Oxygen linked pyrimidine derivatives
WO2009127642A2 (en) 2008-04-15 2009-10-22 Cellzome Limited Use of lrrk2 inhibitors for neurodegenerative diseases
BR112012006859A2 (pt) 2009-09-29 2019-09-24 Glaxo Group Ltd compostos
AU2011256380C1 (en) * 2010-05-20 2016-09-08 Array Biopharma Inc. Macrocyclic compounds as Trk kinase inhibitors
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
ES2583477T3 (es) * 2011-09-30 2016-09-21 Ipsen Pharma S.A.S. Inhibidores macrocíclicos de cinasa de LRRK2
KR20140078710A (ko) * 2011-09-30 2014-06-25 온코디자인 에스.에이. 거대고리 flt3 키나제 억제제

Similar Documents

Publication Publication Date Title
JP2017529365A5 (enExample)
JP2019536785A5 (enExample)
JP2016506369A5 (enExample)
JP2015509535A5 (enExample)
JP2020502092A5 (enExample)
RU2016143333A (ru) Амидные производные и их фармацевтически приемлемые соли, способ их получения и медицинское применение
AR103064A1 (es) Compuestos moduladores de fxr (nr1h4)
JP2015514808A5 (enExample)
JP2015531773A5 (enExample)
JP2016525135A5 (enExample)
JP2018519343A5 (enExample)
PE20181093A1 (es) Compuestos heterociclicos y usos de los mismos
JP2016510796A5 (enExample)
JP2014506599A5 (enExample)
JP2018522034A5 (enExample)
JP2013532652A5 (enExample)
JP2015504091A5 (enExample)
JP2016507581A5 (enExample)
HRP20210447T1 (hr) Piridinski spoj
RU2014117515A (ru) Макроциклические ингибиторы киназы lrrk2
AR104963A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
JP2017501237A5 (enExample)
JP2016531868A5 (enExample)
CR20200418A (es) Inhibidores de orginasa y sus mètodos de uso antecedentes